-
公开(公告)号:US20120101148A1
公开(公告)日:2012-04-26
申请号:US13147189
申请日:2010-01-29
申请人: Akin Aking , William Querbes , Frances M.P. Wong , Joseph R. Dorkin , Xiaojun Qin , William Cantley , Anna Borodovsky , Soma De , Muthiah Manoharan , Muthusamy Jayaraman , Kallanthottathil G. Rajeev
发明人: Akin Aking , William Querbes , Frances M.P. Wong , Joseph R. Dorkin , Xiaojun Qin , William Cantley , Anna Borodovsky , Soma De , Muthiah Manoharan , Muthusamy Jayaraman , Kallanthottathil G. Rajeev
IPC分类号: A61K31/713 , A61P43/00 , A61K31/7088 , A61K47/42 , A61K47/28 , A61K31/7105
CPC分类号: A61K48/0008 , A61K9/1272
摘要: The invention features an improved lipid formulation comprising a cationic lipid of formula (A), a neutral lipid, a sterol and a PEG or PEG-modified lipid, where R1 and R2 are independently alkyl, alkenyl or alkynyl, each can be optionally substituted, and R3 and R4 are independently lower alkyl or R3 and R4 can be taken together to form an optionally substituted heterocyclic ring. In one embodiment, R1 and R2 are independently selected from oleoyl, pamitoyl, steroyl, linoleyl and R3 and R4 are methyl. Also disclosed are targeting lipids, and specific lipid formulations comprising such targeting lipids.
摘要翻译: 本发明的特征在于改进的脂质制剂,其包含式(A)的阳离子脂质,中性脂质,固醇和PEG或PEG修饰的脂质,其中R 1和R 2独立地为烷基,烯基或炔基,各自可任选被取代, 并且R 3和R 4独立地为低级烷基或R 3和R 4可以一起形成任选取代的杂环。 在一个实施方案中,R 1和R 2独立地选自油酰基,苯甲酰基,甾烷基,亚油酰基,并且R 3和R 4是甲基。 还公开了靶向脂质和包含这种靶向脂质的特定脂质制剂。
-
公开(公告)号:US20110311582A1
公开(公告)日:2011-12-22
申请号:US13128283
申请日:2009-11-10
申请人: Muthiah Manoharan , Muthusamy Jayaraman , Kallanthottathil G. Rajeev , laxman Eltepu , Steven Ansell , Jianxin Chen
发明人: Muthiah Manoharan , Muthusamy Jayaraman , Kallanthottathil G. Rajeev , laxman Eltepu , Steven Ansell , Jianxin Chen
IPC分类号: A61K39/12 , C07D203/08 , A61K47/44 , A61K31/7088 , A61K31/7105 , A61K31/713 , C12N5/071 , C12N15/85 , A61K39/00 , A61K39/02 , A61P37/04 , A61P31/12 , A61P31/04 , A61P33/00 , A61P35/00 , C07C229/30
CPC分类号: A61K47/44 , A61K9/1272 , A61K31/7088 , A61K31/713 , A61K39/00 , A61K39/39 , A61K47/10 , A61K47/18 , A61K47/20 , A61K47/28 , A61K2039/55555 , A61K2039/55561 , C07C229/08 , C07C229/30 , C07C237/16 , C07C251/38 , C07C251/78 , C07C271/12 , C07C271/20 , C07C323/25 , C07D203/10 , C07D317/28 , C07D317/44 , C07D317/46 , C07D317/72 , C07D319/06 , C07D405/12 , C07D491/056 , C07D491/113 , C12N15/111 , C12N15/113 , C12N2310/14 , C12N2310/3515 , C12N2320/32 , Y02A50/464
摘要: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention formula (I) provides lipids having the following structure XXXIII wherein: R1 and R2 are each independently for each occurrence optionally substituted C10-C30 alkyl, optionally substituted C10-C30 alkenyl, optionally substituted C10-C30 alkynyl, optionally substituted C10-C30 acyl, or -linker-ligand; R3 is H, optionally substituted C1-C10 alkyl, optionally substituted C2-C10 alkenyl, optionally substituted C2-C10 alkynyl, alky lhetro cycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ω-aminoalkyls, ω-(substituted)aminoalkyls, ω-phosphoalkyls, ω-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; and E is C(O)O or OC(O).
摘要翻译: 本发明提供有利地用于脂质颗粒以用于体内递送治疗剂至细胞的脂质。 具体地,本发明式(I)提供具有以下结构XXXIII的脂质,其中:R1和R2各自独立地为任何取代的C 10 -C 30烷基,任选取代的C 10 -C 30烯基,任选取代的C 10 -C 30炔基,任选取代的 C10-C30酰基或 - 连接子 - 配体; R 3是H,任选取代的C 1 -C 10烷基,任选取代的C 2 -C 10烯基,任选取代的C 2 -C 10炔基,烷基杂芳基,烷基磷酸酯,烷基硫代磷酸酯,烷基磷酸二烷基酯,烷基膦酸酯,烷基胺,羟基烷基,ω-氨基烷基,ω-(取代的) 氨基烷基,ω-磷酸烷基酯,ω-硫代磷酰基烷基,任选取代的聚乙二醇(PEG,mw 100-40K),任选取代的mPEG(mw 120-40K),杂芳基,杂环或连接体 - 配体; 并且E是C(O)O或OC(O)。
-
公开(公告)号:US08802644B2
公开(公告)日:2014-08-12
申请号:US13357856
申请日:2012-01-25
申请人: Jianxin Chen , Steven Ansell , Akin Akinc , Joseph Robert Dorkin , Xiaojun Qin , William Cantley , Muthiah Manoharan , Kallanthottathil G. Rajeev , Jayaprakash K. Narayanannair , Muthusamy Jayaraman
发明人: Jianxin Chen , Steven Ansell , Akin Akinc , Joseph Robert Dorkin , Xiaojun Qin , William Cantley , Muthiah Manoharan , Kallanthottathil G. Rajeev , Jayaprakash K. Narayanannair , Muthusamy Jayaraman
IPC分类号: C12N15/113 , C07C229/06 , A61K47/12 , A61K47/14
CPC分类号: A61K9/1272 , A61K9/1278 , A61K31/22 , A61K31/7088 , A61K31/712 , A61K31/713 , A61K38/1709 , A61K38/4846 , A61K47/14 , A61K47/549 , A61K47/551 , A61K47/6911 , A61K48/0033 , C07C29/58 , C07C227/18 , C07C227/40 , C07C229/12 , C07D475/04 , C12N15/113 , C12N15/1137 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/341 , C12N2310/346 , C12N2310/351 , C12N2310/3515 , C12N2320/32 , Y02A50/463 , A61K2300/00 , C12N2310/3521 , C12N2310/3533
摘要: The invention features a cationic lipid of formula I, an improved lipid formulation comprising a cationic lipid of formula I and corresponding methods of use. Also disclosed are targeting lipids, and specific lipid formulations comprising such targeting lipids.
摘要翻译: 本发明的特征在于式I的阳离子脂质,包含式I的阳离子脂质和相应的使用方法的改进的脂质制剂。 还公开了靶向脂质和包含这种靶向脂质的特定脂质制剂。
-
公开(公告)号:US20120183602A1
公开(公告)日:2012-07-19
申请号:US13357856
申请日:2012-01-25
申请人: Jianxin CHEN , Steven Ansell , Akin Akinc , Joseph Robert Dorkin , Xiaojun Qin , William Cantley , Muthiah Manoharan , Kallanthottathil G. Rajeev , Jayaprakash K. Narayanannair , Muthusamy Jayaraman
发明人: Jianxin CHEN , Steven Ansell , Akin Akinc , Joseph Robert Dorkin , Xiaojun Qin , William Cantley , Muthiah Manoharan , Kallanthottathil G. Rajeev , Jayaprakash K. Narayanannair , Muthusamy Jayaraman
IPC分类号: A61K9/127 , A61K31/7088 , C12N5/02 , A61K47/44
CPC分类号: A61K9/1272 , A61K9/1278 , A61K31/22 , A61K31/7088 , A61K31/712 , A61K31/713 , A61K38/1709 , A61K38/4846 , A61K47/14 , A61K47/549 , A61K47/551 , A61K47/6911 , A61K48/0033 , C07C29/58 , C07C227/18 , C07C227/40 , C07C229/12 , C07D475/04 , C12N15/113 , C12N15/1137 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/341 , C12N2310/346 , C12N2310/351 , C12N2310/3515 , C12N2320/32 , Y02A50/463 , A61K2300/00 , C12N2310/3521 , C12N2310/3533
摘要: The invention features a cationic lipid of formula I, an improved lipid formulation comprising a cationic lipid of formula I and corresponding methods of use. Also disclosed are targeting lipids, and specific lipid formulations comprising such targeting lipids.
摘要翻译: 本发明的特征在于式I的阳离子脂质,包含式I的阳离子脂质和相应的使用方法的改进的脂质制剂。 还公开了靶向脂质和包含这种靶向脂质的特定脂质制剂。
-
公开(公告)号:US20090247614A1
公开(公告)日:2009-10-01
申请号:US12328537
申请日:2008-12-04
申请人: Muthiah Manoharan , Kallanthottathil G. Rajeev , Muthusamy Jayaraman , Jayaprakash K. Narayanannair
发明人: Muthiah Manoharan , Kallanthottathil G. Rajeev , Muthusamy Jayaraman , Jayaprakash K. Narayanannair
IPC分类号: A61K31/7088 , C07H21/02 , C12N5/02
CPC分类号: C12N15/113 , A61K47/55
摘要: The present invention provides iRNA agent including at least one monomer having the structure shown in formula (I′) wherein: A and B are each independently for each occurrence O, N(RN) or S; X is H, a protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z′)(Z″)O-nucleoside, —P(Z′)(Z″)O-oligonucleotide, a lipid, a PEG, a steroid, a polymer, —P(Z′)(Z″)O-L6-Q′-L7-OP(Z′″)(Z″″)O-oligonucleotide, a nucleotide, or an oligonucleotide; Y is H, a protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z′)(Z″)O-nucleoside, —P(Z′)(Z″)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z′)(Z″)O-L6-Q′-L7-OP(Z′″)(Z″″)O-oligonucleotide, a nucleotide, or an oligonucleotide; R is folate, a folate analog a folate mimic or a folate receptor binding ligand; L6 and L1 are each independently for each occurrence —(CH2)n—, —C(R′)(R″)(CH2)n—, —(CH2)nC(R′)(R″)—, —(CH2CH2O)mCH2CH2—, or —(CH2CH2O)mCH2CH2NH—; Q′ is NH, O, S, CH2, C(O)O, C(O)NH, —NH—CH(Ra)—C(O)—, —C(O)—CH(Ra)—NH—, CO, where Ra is H or amino acid side; chain. R′ and R″ are each independently H, CH3, OH, SH, NH2, NH(Alkyl=Me, Et, Pr, isoPr, Bu, Bn) or N(diAlkyl=Me2, Et2, Bn2); Z′, Z″, Z′″ and Z″″ are independently O or S; n represent independently for each occurrence 1-20; and m represent independently for each occurrence 0-50.
摘要翻译: 本发明提供包含至少一种具有式(I')所示结构的单体的iRNA试剂,其中:A和B各自独立地为O,N(RN)或S; X是H,保护基,磷酸基,磷酸二酯基,活化磷酸酯基,活化亚磷酸酯基,亚磷酰胺,固体载体,-P(Z')(Z“)O-核苷,-P (Z')(Z“)O-寡核苷酸,脂质,PEG,类固醇,聚合物,-P(Z')(Z”)O-L6-Q'-L7-OP(Z“ ')(Z“”)O-寡核苷酸,核苷酸或寡核苷酸; Y是H,保护基,磷酸基,磷酸二酯基,活化磷酸酯基,活化亚磷酸酯基,亚磷酰胺,固体载体,-P(Z')(Z“)O-核苷,-P (Z')(Z“)(Z”)O-寡核苷酸,脂质,PEG,类固醇,亲脂性,聚合物,-P(Z')(Z“)O-L6-Q'-L7-OP Z“')(Z”“)O-寡核苷酸,核苷酸或寡核苷酸; R是叶酸,叶酸类似物叶酸类似物或叶酸受体结合配体; (CH 2)n - , - (R')(R“)(CH 2)n - , - (CH 2)n C(R')(R”) - , - (CH 2 CH 2 O)mCH 2 CH 2 - 或 - (CH 2 CH 2 O)m CH 2 CH 2 NH-; Q'是NH,O,S,CH2,C(O)O,C(O)NH,-NH-CH(Ra)-C(O) - , - (O)-CH(Ra) ,CO,其中Ra为H或氨基酸侧; 链。 R'和R“各自独立地为H,CH 3,OH,SH,NH 2,NH(烷基= Me,Et,Pr,isoPr,Bu,Bn)或N(二烷基= Me 2,Et 2,Bn 2); Z',Z“,Z”“和”Z“独立地为O或S; n每次出现1-20,独立地表示1-20; 而m代表每次出现的0-50。
-
公开(公告)号:US20130017223A1
公开(公告)日:2013-01-17
申请号:US13516335
申请日:2010-12-17
申请人: Michael J Hope , Thomas D. Madden , Pieter R. Cullis , Martin Maier , Muthusamy Jayaraman , Kallanthottathil G. Rajeev , Akin Akinc , Muthiah Manoharan
发明人: Michael J Hope , Thomas D. Madden , Pieter R. Cullis , Martin Maier , Muthusamy Jayaraman , Kallanthottathil G. Rajeev , Akin Akinc , Muthiah Manoharan
IPC分类号: A61K47/24 , A61K47/28 , A61P37/04 , A61K31/713 , C12N5/071 , C12N15/85 , A61K31/7088 , A61K31/7105
CPC分类号: A61K47/543 , A61K9/1272 , A61K47/6911 , C12N15/88
摘要: A lipid particle can include a plurality of cationic lipids, such as a first cationic lipid and a second cationic lipid. The first cationic lipid can be selected on the basis of a first property and the second cationic can be selected on the basis of a second property. The first and second properties are complementary. The attributes of the lipid particle can reflect the selected properties of the cationic lipids, and the complementary nature of those properties.
摘要翻译: 脂质颗粒可以包括多个阳离子脂质,例如第一阳离子脂质和第二阳离子脂质。 可以基于第一性质选择第一阳离子脂质,并且可以基于第二性质选择第二阳离子脂质。 第一和第二属性是互补的。 脂质颗粒的属性可以反映阳离子脂质的选择性质,以及这些性质的互补性质。
-
公开(公告)号:US08158601B2
公开(公告)日:2012-04-17
申请号:US12813448
申请日:2010-06-10
申请人: Jianxin Chen , Steven Ansell , Akin Akinc , Joseph Robert Dorkin , Xiaojun Qin , William Cantley , Muthiah Manoharan , Kallanthottathil G. Rajeev , Jayaprakash K. Narayanannair , Muthusamy Jayaraman
发明人: Jianxin Chen , Steven Ansell , Akin Akinc , Joseph Robert Dorkin , Xiaojun Qin , William Cantley , Muthiah Manoharan , Kallanthottathil G. Rajeev , Jayaprakash K. Narayanannair , Muthusamy Jayaraman
IPC分类号: A61K31/70 , A61K47/00 , C07C229/00
CPC分类号: A61K9/1272 , A61K9/1278 , A61K31/22 , A61K31/7088 , A61K31/712 , A61K31/713 , A61K38/1709 , A61K38/4846 , A61K47/14 , A61K47/549 , A61K47/551 , A61K47/6911 , A61K48/0033 , C07C29/58 , C07C227/18 , C07C227/40 , C07C229/12 , C07D475/04 , C12N15/113 , C12N15/1137 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/341 , C12N2310/346 , C12N2310/351 , C12N2310/3515 , C12N2320/32 , Y02A50/463 , A61K2300/00 , C12N2310/3521 , C12N2310/3533
摘要: The invention features a cationic lipid of formula I, an improved lipid formulation comprising a cationic lipid of formula I and corresponding methods of use. Also disclosed are targeting lipids, and specific lipid formulations comprising such targeting lipids.
摘要翻译: 本发明的特征在于式I的阳离子脂质,包含式I的阳离子脂质和相应的使用方法的改进的脂质制剂。 还公开了靶向脂质和包含这种靶向脂质的特定脂质制剂。
-
公开(公告)号:US20100324120A1
公开(公告)日:2010-12-23
申请号:US12813448
申请日:2010-06-10
申请人: Jianxin Chen , Steven Ansell , Akin Akinc , Joseph Robert Dorkin , Xiaojun Qin , William Cantley , Muthiah Manoharan , Kallanthottathil G. Rajeev , Jayaprakash K. Narayanannair , Muthusamy Jayaraman
发明人: Jianxin Chen , Steven Ansell , Akin Akinc , Joseph Robert Dorkin , Xiaojun Qin , William Cantley , Muthiah Manoharan , Kallanthottathil G. Rajeev , Jayaprakash K. Narayanannair , Muthusamy Jayaraman
IPC分类号: A61K31/711 , C07C229/30 , A61K47/16 , A61K31/713 , A61K47/26 , C12N5/00 , A61P43/00
CPC分类号: A61K9/1272 , A61K9/1278 , A61K31/22 , A61K31/7088 , A61K31/712 , A61K31/713 , A61K38/1709 , A61K38/4846 , A61K47/14 , A61K47/549 , A61K47/551 , A61K47/6911 , A61K48/0033 , C07C29/58 , C07C227/18 , C07C227/40 , C07C229/12 , C07D475/04 , C12N15/113 , C12N15/1137 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/341 , C12N2310/346 , C12N2310/351 , C12N2310/3515 , C12N2320/32 , Y02A50/463 , A61K2300/00 , C12N2310/3521 , C12N2310/3533
摘要: The invention features a cationic lipid of formula I, an improved lipid formulation comprising a cationic lipid of formula I and corresponding methods of use. Also disclosed are targeting lipids, and specific lipid formulations comprising such targeting lipids.
摘要翻译: 本发明的特征在于式I的阳离子脂质,包含式I的阳离子脂质和相应的使用方法的改进的脂质制剂。 还公开了靶向脂质和包含这种靶向脂质的特定脂质制剂。
-
公开(公告)号:US20090247608A1
公开(公告)日:2009-10-01
申请号:US12328669
申请日:2008-12-04
申请人: Muthiah Manoharan , Kallanthottathil G. Rajeev , Gayaprakash K. Narayananovair , Muthusamy Jayaraman
发明人: Muthiah Manoharan , Kallanthottathil G. Rajeev , Gayaprakash K. Narayananovair , Muthusamy Jayaraman
IPC分类号: A61K31/713 , C07K14/00 , A61K47/42 , A61K31/7088 , C07K7/04 , C07K5/04 , A61K47/12
摘要: The present invention provides targeting lipids of structure L100—linker—L101 (CI), where L100 is a lipid, lipophile, alkyl, alkenyl or alkynyl, L101 is a ligand or —CH2CH2(OCH2CH2)pO(CH2)qCH2-ligand, p is 1-1000, and q is 1-20. In addition, the invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo.
摘要翻译: 本发明提供了结构<?in-line-formula description =“In-line Formulas”end =“lead”?> L100-linker-L101(CI),<?in-line-formula description =“In 其中L100是脂质,亲脂性,烷基,烯基或炔基,L101是配体或-CH2CH2(OCH2CH2)pO(CH2)qCH2-配体,p是1-1000,和 q是1-20。 此外,本发明提供了将治疗剂递送至细胞的组合物和方法。 特别地,这些包括提供核酸的有效包封的新型脂质和核酸 - 脂质颗粒,并将包封的核酸有效地递送到细胞体内。
-
公开(公告)号:US20120071641A1
公开(公告)日:2012-03-22
申请号:US13203927
申请日:2010-03-02
申请人: Muthiah Manoharan , Kallanthottathil G. Rajeev , Alexander V. Kelin , Sudhakar Rao Takkellapati , Shigeo Matsuda
发明人: Muthiah Manoharan , Kallanthottathil G. Rajeev , Alexander V. Kelin , Sudhakar Rao Takkellapati , Shigeo Matsuda
IPC分类号: C07H21/02 , C07H19/167 , C07H19/10 , C07H19/067 , C07H21/00 , C07H19/20
CPC分类号: C12N15/113 , C07H19/073 , C07H19/10 , C07H19/173 , C07H19/20 , C07H21/00 , C07H21/02 , C12N15/1137 , C12N2310/14 , C12N2310/32 , C12N2310/321 , C12N2310/322 , C12N2310/334 , C12N2310/335 , C12N2310/336
摘要: The present invention provides nucleosides of formula (1) and oligonucleotides comprising at least one nucleoside of formula (2): Another aspect of the invention relates to a method of inhibiting the expression of a gene in cell, the method comprising (a) contacting an oligonucleotide of the invention with the cell; and (b) maintaining the cell from step (a) for a time sufficient to obtain degradation of the mRNA of the target gene.
摘要翻译: 本发明提供式(1)的核苷和包含至少一种式(2)的核苷的寡核苷酸:本发明的另一方面涉及抑制细胞中基因表达的方法,所述方法包括(a)使 本发明的寡核苷酸与细胞; 和(b)将来自步骤(a)的细胞维持足以获得靶基因的mRNA降解的时间。
-
-
-
-
-
-
-
-
-